Official announcement|This GLP-1 RA weekly preparation was approved, adding a "weapon" to blood glucose management, and comprehensive benefits for patients

Multi-faceted assistance in diabetes management, adding a new "good helper" to the clinic.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new type of hypoglycemic agent that has received widespread attention and welcome in recent years because it can effectively control blood sugar, improve β cell function, reduce weight and reduce systolic blood pressure.
1.

Recently, a GLP-1 RA drug-smeglutide weekly preparation was officially approved for marketing by the National Medical Products Administration (NMPA) of China.
The indications include: · On the basis of diet control and exercise, receiving metformin and/ Or sulfonylureas for the treatment of adult type 2 diabetes (T2DM) patients with poor blood sugar control.

 · It is suitable for reducing the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adult T2DM patients with cardiovascular disease.

 Semaglutide is actually known as semaglutide, and the name officially approved in China this time is semaglutide.

As a long-acting analog of human glucagon-like peptide-1 (GLP-1), it promotes insulin secretion and inhibits glucagon secretion through a glucose concentration-dependent mechanism.
Through innovative peptide chain optimization, it has a long half-life For 7 days, it only needs to be administered once a week to effectively control sugar2.

What breakthroughs and upgrades does the approval of smeglutide bring to diabetes management? Let's take a set next.

Strongly reduce blood sugar, HbA1c is reduced by 1.
8%, and the compliance rate is 86.
1%3! The first priority of hypoglycemic drugs is hypoglycemia.
In terms of hypoglycemic effect, a number of clinical studies have shown that smegaglutide can reduce glycosylated hemoglobin (HbA1c) by 1.
5% to 1.
8% in patients with T2DM, which is better than Sieger.
The positive control groups such as gliptin, exenatide weekly preparation, dulaglutide, canagliflozin, liraglutide, and insulin glargine (Figure 1) 4-9.

 Figure 1.
Results of the SUSTAIN series of studies In the Chinese population, the hypoglycemic effect of smeglutide is also very significant.

By analyzing the results of 605 Chinese patients in the SUSTAIN China study, it was found that the HbA1c of patients treated with smeglutide 1.
0 mg/week decreased by as much as 1.
8% (Figure 2), which was significantly better than the sitagliptin group3.

 Figure 2.
The reduction of HbA1c in the Chinese subgroup of patients at 30 weeks is the guarantee for increasing the HbA1c compliance rate.
In the SUSTAIN China Chinese population, after 30 weeks of treatment, the treatment group with smeglutide 1.
0mg/week reached HbA1c< 7% of patients with glycemic control goals are as high as 86.
1% (Figure 3)3.

Figure 3.
Comparison of the HbA1c compliance rate of the Chinese subgroup of patients after 30 weeks of treatment.
High reduction and strong compliance.
The effectiveness of the once-a-week semaglutide treatment for Chinese patients and the rate of compliance have been confirmed.

 Comprehensive benefits of cardiovascular metabolism, the risk of MACE is reduced by 26%! Previously, the emergence of evidence-based evidence for the cardiovascular benefits of several GLP-1 RA drugs made them stand on the front line recommended by the guidelines 10-11.

In 2021, the "Diagnostic Standards for Diabetes Medicine" promulgated by the American Diabetes Association (ADA) recommends it as one of the preferred drugs for patients with high risk factors for cardiovascular disease or diagnosed atherosclerotic cardiovascular disease (ASCVD) 12 .

 As a GLP-1 RA, smegaglutide also has cardiovascular benefits.

 Cardiovascular Outcome Trial (CVOT)-SUSTAIN 6 results showed that among patients with high cardiovascular risk of T2DM, the risk of major cardiovascular adverse events (MACE) in patients treated with semaglutide was significantly lower than that in the placebo group26 %.

Mainly driven by a reduction in the risk of non-fatal stroke (a significant reduction of 39%)13.

 In addition, smeglutide can significantly improve the cardiovascular and metabolic indicators of patients and help patients benefit comprehensively.

In the study, the patient's waist circumference, weight, blood pressure, total cholesterol, triglyceride and other data were significantly improved after treatment with smeglutide3,14.

 "On-demand" lowering blood sugar and weight, the drug is more "smart" As a new type of blood sugar lowering drug that takes into account both potent blood sugar lowering and cardiovascular metabolic benefits, smegaglutide can also achieve "smart" blood sugar and weight reduction.

 The summary analysis of SUSTAIN1-5 found that simegliutide can significantly reduce HbA1c regardless of background treatment and regardless of the length of the disease.
The higher the baseline HbA1c, the greater the blood sugar reduction after simegliutide (Figure 4), and the lower it is.
The risk of blood sugar is extremely low, and it can truly achieve "on-demand" and "low-glycemic but not low-glycemic", taking into account the effectiveness and safety of treatment 15
 Figure 4.
The higher the patient's baseline HbA1c, the greater the reduction in HbA1c after simegliutide treatment.
In addition, simegliutide can also lose weight "on demand".

 A number of studies have shown that smeglutide can significantly reduce weight, and comprehensively SUSTAIN 1-5 can also be found that its weight loss effect is based on the patient's body mass index (BMI) "smart" weight loss, patients with BMI<25kg/m2 The weight loss is relatively small (Figure 5), so non-overweight/obese patients can also use 15-16 with confidence.

 *p<0.
05 vs placebo group Figure 5.
In the SUSTAIN 1 study, the "smart" weight loss drug of smeglutide was approved, and we will create a future together with the development of treatment concepts and the continuous production of innovative drugs to provide patients with The hypoglycemic option that takes into account the benefits of cardiovascular metabolism has become the common goal of type 2 diabetes treatment and drug development.

The approval of smeglutide in China gives T2DM patients in my country a new option that combines the combined benefits of potent hypoglycemic and cardiovascular metabolism.
Once a week, the stable control of sugar can help patients return to life in peace.

We look forward to more new-type hypoglycemic drugs like smegaglutide entering the Chinese market to benefit more Chinese patients in the future! References: 1.
JJ Meier, et al.
Nat Rev Endocrinol.
2012;8:728-742.
2.
Lau J, et al.
J Med Chem 2015;58:7370–803.
Ji L, et al.
Diabetes Obes Metab.
2021;23(2):404-414.
4.
Ahmann AJ, et al.
Diabetes Care.
2018;41(2):258-266.
5.
Aroda VR, et al.
Lancet Diabetes Endocrinol.
2017;5(5): 355-366.
6.
Ahren B, et al.
Lancet Diabetes Endocrinol 2017; 5: 341–54.
7.
Lingvay I, et al.
Lancet Diabetes Endocrinol.
2019;7(11):834-844.
8.
Pratley RE, et al.
Lancet Diabetes Endocrinol.
2018;6(4):275-286.
9.
Capehorn MS, et al.
Diabetes Metab.
2020;46(2):100-109.
10.
Marso SP, et al.
N Engl J Med.
2016; 375(4):311-22.
11.
Gerstein HC, et al.
Lancet.
2019;394(10193):121-130.
12.
American Diabetes Association.
Diabetes Care.
2021;44(Suppl 1):S111-S124.
13.
Marso SP, et al.
N Engl J Med.
2017;376(9):891-2.
14.
Zinman B, et al.